Acer Therapeutics Story

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;'>AT</div>
ACER -- USA Stock  

USD 3.15  0.04  1.25%

The upcoming quarterly report is expected on the 17th of March 2021. The stock is currently experiencing an active upward rally. Acer Therapeutics Current Ratio is relatively stable at the moment as compared to the past year. Acer Therapeutics reported last year Current Ratio of 5.35. As of 01/15/2021, Debt to Equity Ratio is likely to grow to 0.18, while Earnings before Tax are likely to drop (27.2 M). As many investors are getting excited about healthcare space, it is fair to sum up Acer Therapeutics as an investment option. What exactly are Acer Therapeutics shareholders getting in February?
Published over a month ago
View all stories for Acer Therapeutics | View All Stories
You think Acer Therapeutics (NASDAQ:ACER) debt is an issue for retail investors?
This firm currently holds 995.54 K in liabilities with Debt to Equity (D/E) ratio of 0.09, which may suggest the firm is not taking enough advantage from borrowing. On a scale of 0 to 100, Acer Therapeutics holds a performance score of 7. The firm shows a Beta (market volatility) of 0.9197, which signifies possible diversification benefits within a given portfolio. Let's try to break down what Acer Therapeutics's beta means in this case. Acer Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, Acer Therapeutics is expected to follow. Although it is vital to follow Acer Therapeutics historical returns, it is good to be conservative about what you can do with the information regarding equity current trending patterns. The philosophy in foreseeing future performance of any stock is to evaluate the business as a whole together with its past performance, including all available fundamental and technical indicators. We have found twenty-seven technical indicators for Acer Therapeutics, which you can use to evaluate the performance of the firm. Please makes use of Acer Therapeutics coefficient of variation, potential upside, rate of daily change, as well as the relationship between the sortino ratio and skewness to make a quick decision on whether Acer Therapeutics price patterns will revert.
Acer Therapeutics financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures the total debt position of Acer Therapeutics, including all of Acer Therapeutics's outstanding debt obligations, and compares it with the equity. In simple terms, the high financial leverage means the cost of production, together with running the business day-to-day, is high, whereas, lower financial leverage implies lower fixed cost investment in the business and generally considered by investors to be a good sign. So if creditors own a majority of Acer Therapeutics assets, the company is considered highly leveraged. Understanding the composition and structure of overall Acer Therapeutics debt and outstanding corporate bonds gives a good idea of how risky the capital structure of a business is and if it is worth investing in it.
Please read more on our technical analysis page.

Understanding Acer Therapeutics Total Liabilities

Acer Therapeutics liabilities are broken down into two parts on the balance sheet. These are short-term (or current) obligations and long-term debt. Acer Therapeutics has to fulfill its short-term liabilities in this reporting year and should be no more than 12 months old. Long-term debt, on the other hand, is anything beyond the 12-month payment timeframe. Common short-term liabilities found on Acer Therapeutics balance sheet include debt obligations and money owed to different Acer Therapeutics vendors, workers, and loan providers. Below is the chart of Acer Therapeutics short long-term liabilities accounts currently reported on its balance sheet.
You can use Acer Therapeutics financial leverage analysis tool to get a better grip on understanding its financial position

How important is Acer Therapeutics's Liquidity

Acer Therapeutics financial leverage refers to using borrowed capital as a funding source to finance Acer Therapeutics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Acer Therapeutics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Acer Therapeutics's total debt and its cash.

Breaking down Acer Therapeutics Indicators

The latest price spike of Acer Therapeutics could raise concerns from retail investors as the firm it trading at a share price of 3.85 on 19,654,466 in volume. The company executives may have good odds in positioning the firm resources to exploit market volatility in February. The stock standard deviation of daily returns for 30 days investing horizon is currently 5.66. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Acer Therapeutics partners.

Asset Breakdown

10.6 M
Assets Non Current
15.7 M
Current Assets
Total Assets22.77 Million
Current Assets15.66 Million
Assets Non Current10.65 Million
Goodwill7.99 Million

Our perspective of the latest Acer Therapeutics spike

Latest Sortino Ratio is up to -0.02. Price may fall again. Acer Therapeutics currently demonstrates below-verage downside deviation. It has Information Ratio of -0.02 and Jensen Alpha of -0.05. However, we do advice investors to further question Acer Therapeutics expected returns to ensure all indicators are consistent with the current outlook about its relatively low value at risk.

While few other entities under the biotechnology industry are still a bit expensive, Acer Therapeutics may offer a potential longer-term growth to retail investors. Taking everything into account, as of the 15th of January 2021, we see that Acer Therapeutics almost mirrors the market. The enterprise is undervalued with very low probability of distress within the next 24 months. Our up-to-date 30 days 'Buy-vs-Sell' recommendation on the enterprise is Strong Hold.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Acer Therapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to